InsiderSource
ALKS

Alkermes plc.

SEC CIK 1520262
$44.28 +29.7% · 90 days
90-day buys
$0
0 open-market
90-day sells
$2M
8 open-market
Net insider flow
−$2M
Net selling
Filings shown
73
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at ALKS have sold a net $2M of stock (0 open-market buys vs 8 sells).

Largest recent trade: Hopkinson Craig C. sold $5.62M of ALKS, trimming their stake 65%.

Most active filer: Hopkinson Craig C., with 29 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for ALKS, newest first
View on SEC EDGAR ↗
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Apr 1, 2026 ΔOwn −9.5%

Hopkinson Craig C. sold $319.6K of ALKS, trimming their stake 10%.

−$319.6K
9,000 sh @ $36
ALKS
Alkermes plc.
Sell Gaffin David Joseph · EVP, CLO, Alkermes, Inc. · Open-market sale · filed Mar 4, 2026 ΔOwn −0.9%

Gaffin David Joseph sold $60.5K of ALKS, trimming their stake 1%.

−$60.5K
2,034 sh @ $30
ALKS
Alkermes plc.
Sell Parisi Samuel Joseph · VP, Finance (Interim PAO) · Open-market sale · filed Mar 4, 2026 ΔOwn −47%

Parisi Samuel Joseph sold $201.8K of ALKS, trimming their stake 47%.

−$201.8K
6,890 sh @ $29
ALKS
Alkermes plc.
Sell Nichols Christian Todd · SVP, Chief Commercial Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −5.2%

Nichols Christian Todd sold $180K of ALKS, trimming their stake 5%.

−$180K
6,000 sh @ $30
ALKS
Alkermes plc.
Option exercise Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Option exercise · filed Mar 4, 2026 ΔOwn +5.4%
+$96.7K
5,000 sh @ $19
Advertisement
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −9.1%

Hopkinson Craig C. sold $267.5K of ALKS, trimming their stake 9%.

−$267.5K
9,000 sh @ $30
ALKS
Alkermes plc.
Sell Gaffin David Joseph · EVP, CLO, Alkermes, Inc. · Open-market sale · filed Mar 4, 2026 ΔOwn −0.8%

Gaffin David Joseph sold $59.6K of ALKS, trimming their stake 1%.

−$59.6K
2,034 sh @ $29
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Feb 2, 2026 ΔOwn −7.5%

Hopkinson Craig C. sold $171.2K of ALKS, trimming their stake 7%.

−$171.2K
5,000 sh @ $34
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Feb 2, 2026 ΔOwn −6.5%

Hopkinson Craig C. sold $134.2K of ALKS, trimming their stake 6%.

−$134.2K
4,000 sh @ $34
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Jan 8, 2026 ΔOwn −7.5%

Hopkinson Craig C. sold $150K of ALKS, trimming their stake 7%.

−$150K
5,000 sh @ $30
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Jan 2, 2026 ΔOwn −6.1%

Hopkinson Craig C. sold $112K of ALKS, trimming their stake 6%.

−$112K
4,000 sh @ $28
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Dec 5, 2025 ΔOwn −5.4%

Hopkinson Craig C. sold $112.4K of ALKS, trimming their stake 5%.

−$112.4K
3,748 sh @ $30
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Dec 1, 2025 ΔOwn −5.7%

Hopkinson Craig C. sold $117.2K of ALKS, trimming their stake 6%.

−$117.2K
4,000 sh @ $29
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Nov 3, 2025 ΔOwn −11%

Hopkinson Craig C. sold $273.4K of ALKS, trimming their stake 11%.

−$273.4K
9,000 sh @ $30
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Oct 15, 2025 ΔOwn −11%

Hopkinson Craig C. sold $283.8K of ALKS, trimming their stake 11%.

−$283.8K
9,000 sh @ $32
ALKS
Alkermes plc.
Sell Parisi Samuel Joseph · VP, Finance (Interim PAO) · Open-market sale · filed Feb 28, 2025 ΔOwn −20%

Parisi Samuel Joseph sold $65.9K of ALKS, trimming their stake 20%.

−$65.9K
1,938 sh @ $34
ALKS
Alkermes plc.
Sell Parisi Samuel Joseph · VP, Finance (Interim PAO) · Open-market sale · filed Feb 25, 2025 ΔOwn −33%

Parisi Samuel Joseph sold $132K of ALKS, trimming their stake 33%.

−$132K
3,743 sh @ $35
ALKS
Alkermes plc.
Sell Parisi Samuel Joseph · VP, Finance (Interim PAO) · Open-market sale · filed Feb 20, 2025 ΔOwn −15%

Parisi Samuel Joseph sold $47.4K of ALKS, trimming their stake 15%.

−$47.4K
1,327 sh @ $36
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Feb 14, 2025 ΔOwn −18%

Hopkinson Craig C. sold $1.21M of ALKS, trimming their stake 18%.

−$1.21M
35,586 sh @ $34
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Feb 14, 2025 ΔOwn −65%

Hopkinson Craig C. sold $3.92M of ALKS, trimming their stake 65%.

−$3.92M
108,833 sh @ $36
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Feb 14, 2025 ΔOwn −65%

Hopkinson Craig C. sold $5.62M of ALKS, trimming their stake 65%.

−$5.62M
171,813 sh @ $33
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Feb 14, 2025 ΔOwn −36%

Hopkinson Craig C. sold $1.1M of ALKS, trimming their stake 36%.

−$1.1M
33,108 sh @ $33
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Jan 31, 2025 ΔOwn −69%

Hopkinson Craig C. sold $3.23M of ALKS, trimming their stake 69%.

−$3.23M
100,918 sh @ $32
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Dec 9, 2024 ΔOwn −56%

Hopkinson Craig C. sold $1.96M of ALKS, trimming their stake 56%.

−$1.96M
61,151 sh @ $32
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Dec 5, 2024 ΔOwn −13%

Hopkinson Craig C. sold $290.5K of ALKS, trimming their stake 13%.

−$290.5K
9,221 sh @ $32
ALKS
Alkermes plc.
Sell Hopkinson Craig C. · EVP R&D, Chief Medical Officer · Open-market sale · filed Dec 4, 2024 ΔOwn −17%

Hopkinson Craig C. sold $441.6K of ALKS, trimming their stake 17%.

−$441.6K
14,349 sh @ $31
Advertisement

About ALKS insider activity

This page tracks every recent Form 4 filed for Alkermes plc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is ALKS insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Alkermes plc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.